Literature DB >> 3533395

The contribution of PGI2 to the effects of captopril in conscious dogs in differing states of sodium balance.

M L Watson, R L Jones.   

Abstract

There is some evidence that increased prostaglandin synthesis may mediate some of the effects of the angiotensin converting enzyme inhibitor captopril. The potential role of prostaglandin (PG)I2 in this process was assessed by measurement of changes in urinary 6-keto-PGF1 alpha excretion after captopril in eight sodium replete and depleted conscious dogs. In sodium replete animals captopril induced a small decrease in blood pressure, transient increases in effective renal plasma flow and urinary 6-keto-PGF1 alpha excretion, and progressive increases in plasma renin activity (PRA) and urinary sodium excretion. By contrast, during sodium depletion captopril induced a large decrease in blood pressure, a transient increase in effective renal plasma flow and urinary 6-keto-PGF1 alpha excretion, an early large but transient increase in PRA and small progressive increase in sodium excretion. The time course of changes after captopril suggested that increased PGI2 synthesis may contribute to the transient decrease in renal vascular resistance. The increase in PRA during sodium depletion was not associated with any change in urinary 6-keto-PGF1 alpha excretion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3533395     DOI: 10.1042/cs0710533

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  2 in total

1.  Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity.

Authors:  M Kimura; K Umemura; K Kosuge; M Nishimoto; K Ohashi; M Nakashima
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

2.  Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man.

Authors:  T M MacDonald; K Craig; M L Watson
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.